The Patent Trial and Appeal Board issued a final written decision invalidating claims from Exact Sciences’ US Patent No. 11,970,746 after an inter partes review requested by Geneoscopy. The PTAB found all ten challenged claims unpatentable, following an earlier invalidation of Exact’s US Patent No. 11,634,781. Geneoscopy said the rulings remove asserted patent barriers to its ColoSense colorectal screening test and called the decisions critical to protecting patient choice. Exact Sciences said it is evaluating all options, including an appeal to the Federal Circuit. The dispute stems from litigation that began in 2023, and the case remains scheduled for trial in November 2026. The PTAB rulings could reshape intellectual property leverage and competitive dynamics in noninvasive colorectal cancer screening, where Cologuard has been a market leader.